Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3073–3096 of 22,020 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Healthy Volunteers
Interventions: NNC0642-1895, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Methamphetamine Use Disorder
Interventions: Placebo (saline), Tirzepatide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more

Conditions: Obesity & Overweight
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Menlo Park, California • Boston, Massachusetts

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, SEP-363856; Other · Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Tucson, Arizona • Encino, California • Sherman Oaks, California + 13 more

Conditions: Informed Consent
Interventions: CoCo Chatbot; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Freezing of Gait, Parkinson Disease
Interventions: Cleveland Clinic Stair Ambulation and Functional Evaluation of Gait (SAFE-Gait), Moving Overground in a Virtual Environment (MOVE), Multiple Deep Brain Stimulation (DBS) Conditions; Behavioral · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Alopecia Areata
Interventions: Placebo, Ritlecitinib 100 mg, Ritlecitinib 50 mg; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Encinitas, California • Miami, Florida • Skokie, Illinois + 13 more

Conditions: Locally Advanced or Metastatic Solid Tumors
Interventions: 5-fluorouracil, ASP388B, Carboplatin, Oxaliplatin, Pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Lake Success, New York • Fairfax, Virginia

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions: Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Lisocabtagene Maraleucel, Low-Dose Total Body Irradiation, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Fludarabine; Other · Radiation · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Deep Brain Stimulation, PARKINSON DISEASE (Disorder)
Interventions: DBS as part of standard of care; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 30 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Homewood, Alabama

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab); Drug
Lead sponsor: Multitude Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Port Saint Lucie, Florida • Kingwood, Texas

Conditions: Borderline Personality Disorder (BPD)
Interventions: Emotion Regulation Skills Training, Transcranial Magnetic Stimulation (TMS); Behavioral · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 22 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma, IDH-Wildtype
Interventions: Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, EGFR/EGFRvIII Inhibitor WSD0922-FU, Echocardiography Test, Magnetic Resonance Imaging, Temozolomide; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Pneumococcal Disease
Interventions: 20-valent pneumococcal conjugate vaccine (20vPnC), PG4; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 62
States / cities: Birmingham, Alabama • Guntersville, Alabama • Fair Oaks, California + 37 more

Conditions: Atrial Fibrillation
Interventions: Globe Pulsed Field System; Device
Lead sponsor: Kardium Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Jonesboro, Arkansas • Bellevue, Washington

Conditions: Consolidation, HIV, Plasmablastic Lymphoma
Interventions: Elranatamab (Elra); Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Amputation, Amputation of Lower Limb Above Knee, Amputee
Interventions: Bio Leg; Device
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Lung Injury, Allogeneic Stem Cell Transplantation, Cardiovascular Diseases, Interstitial Lung Disease, Lung Allograft Transplantation, Pulmonary Arterial Hypertension
Interventions: 18F-FAPI-74 PET/CT Imaging, [18F]FAPI-74; Diagnostic Test · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19 Respiratory Infection, Influenza
Interventions: RD-X19, RD-X19 Sham; Device
Lead sponsor: David Moss; Federal
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Amnioinfusion, Chorioamnionitis Affecting Fetus or Newborn, Neonatal Brain Injury
Interventions: Intrauterine Pressure Catheter, Standard obstetric care at discretion of delivery provider; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Plasma Cell Leukemia
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more

Conditions: Ventricular Tachycardia
Interventions: Sphere-9 Catheter with the Affera Mapping and Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Littleton, Colorado • Indianapolis, Indiana • Manhasset, New York + 4 more

Conditions: Diabetes During Pregnancy
Interventions: Continuous Glucose Monitoring (Abbott Freestyle Libre), High-Protein Beverage (Genius Gourmet Sparkling Protein Water), Standard Clear Liquid Diet; Device · Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Arginine Vasopressin Deficiency, Hypopituitarism, Oxytocin Deficiency, Pediatric Disease
Interventions: Norethindrone Acetate-Ethinyl Estradiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Chatbot Implementation In The Clinical Informed Consent Process

Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Investigating the Increased Risk of Falls in Individuals With Parkinson's Disease Treated With Deep Brain Stimulation

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Combining Transcranial Magnetic Stimulation With Emotion Regulation Skills Training in Borderline Personality Disorder

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation

HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

Bio Leg: Advancing Mobility (BAM)

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)

Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease